Commentary: Is Tardive Dyskinesia Disappearing?

Drug Induced Movement Disorders: Second Edition

Volumn , Issue , 2008, Pages 302-310

  Lohr, James B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Education and Clinical Center   (United States)

Author keywords

Antipsychotic agents; Permanent td; Risperidone; Sulpiride; Treatment

Indexed keywords

EID: 84890981560     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753217.ch12     Document Type: Chapter

References (51)

1. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an over view. Am J Psychiatry 1981; 138: 297-309.
2. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
3. American Psychiatry Association. Tardive dyskinesia: A task force report of the American Psychiatric Association. American Psychiatric Association, Washington DC, 1992.
4. Lieberman J, Kane J, Woerner M, et al. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 29: 22-26.
5. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52: 756-765.
6. Byne W, White L, Parella M, et al. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriatr Psychiatry 1998; 13: 473-479.
7. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 (suppl 4): 15-20.
8. Caligiuri MP, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363-384.
9. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25: 135-138.
10. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986; 43: 342-346.
11. Akbostanci MC, Atbasoglu EC, Balaban H. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg 1999; 99: 176-181.
12. Keck PE, Jr, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 (suppl 4): 33-38.
13. Casey DE. Spontaneous and tardive dyskinesia: clinical and laboratory studies. J Clin Psychiatry 1985; 46: 42-47.
14. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994; 51: 643-650.
15. Fenton WS, Blyler CR, Wyatt RJ, McGlashan GH. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997; 171: 265-268.
16. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61 (suppl 4): 10-14.
17. Quinn NP. Prevalence of abnormal movement disorders associated with neuroleptics. Am J Psychiatry 1992; 149: 1123-1124.
18. Delwaide PJU, Desseilles M. Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand 1977; 56: 256-262.
19. Weiner WJ, Klawans HL. Lingual-facial-buccal movements in the elderly. J Am Geriatr Soc 1973; 21: 314-317.
20. Lohr JB, Bracha HS. Association of psychosis and movement disorders in the elderly. Psychiatr Clin N Am 1988; 11: 61-81.
21. Caligiuri MP, Lohr JB, Vaughan RM, et al. Fluctuation of tardive dyskinesia. Biol Psychiatry 1995; 38: 336-339.
22. Brown P, Funk SC. Tardive dyskinesia: barriers to the professional recognition of an iatrogenic disease. J Health Soc Behav 1986; 27: 116-132.
23. Weiden PJ, Mann J, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144: 1148-1153.
24. Hansen TE, Brown WL, Weigel RM, et al. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 1992; 14: 340344.
25. Alexopoulos GS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Disord 1979; 167: 125-127.
26. Myslobodsky MS, Tomer R, Holden T, et al. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Disord 1985; 173: 156-160.
27. Lohr JB, Lohr MA, Wasli E, et al. Self-perception of tardive dyskinesia and neuroleptic-induced parkinsonism: a study of clinical correlates. Psychopharmacol Bull 1987; 23: 211-214.
28. Chong SA, Remington G, Mahendran R, et al. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol 2001; 21(2): 235-237.
29. Van Os J, Fahy T, Jones P, et al. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997; 96: 206-216.
30. Van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao extrapyramidal syndromes study III. Am J Psychiatry 1998; 155: 565-567.
31. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19: 203-208.
32. Van Os J, Walsh E, Van Horn E, et al. Tardive dyskinesia in psychosis: are women really more at risk? Acta Psychiatr Scand 1999; 99: 288-293.
33. Schulze TG, Muller DJ, Krauss H, et al. Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia? Eur Psychiatry 2001; 16: 71-74.
34. Woerner MG, Alvir JMJ, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521-1528.
35. Kelly C, McCreadie T, MacEwan T, et al. Nithsdale schizophrenia surveys. 17. Fifteen year review. Br J Psychiatry 1998; 172: 513-517.
36. Modestin J, Stephan PL, Erni T, et al. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000; 42: 223-230.
37. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248-1254.
38. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-719.
39. Beasley CM, Dellva MA, Tamura RB, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30.
40. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61 (suppl 4): 21-26.
41. Glazer WM, Morgenstern H, Pultz JA, et al. Incidence of tardive dyskinesia is lower with quetiapine treatment than with typical antipsychotics in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2000; 41: 206-207.
42. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 150-1155.
43. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 (suppl 4): 12-19.
44. Yassa R, Nair V. Mild tardive dyskinesia: an 8-year follow-up study. Acta Psychiatr Scand 1989; 81: 139-140.
45. Richardson MA, Casey DE, Lin S. Tardive dyskinesia: resolving persisting, new cases-demographics and treatment [abstract]. Biol Psychiatry 1989; 25(7A, suppl): 161A.
46. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836-841.
47. Wyatt RJ, Khot V. Reply to Quinn NP. Am J Psychiatry 1992; 149: 1124.
48. 12 years. Br J Psychiatry 1986; 149: 621-623.
49. Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104.
50. Strakowski SM, DelBello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001; 15: 701-718.
51. Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 2002; 63 (suppl 10): 23-28.